RecruitingNCT06340152
Multi-Omics for Maternal Health After Preeclampsia
Sponsor
University of California, San Diego
Enrollment
1,100 participants
Start Date
Dec 20, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To develop strategies to identify postpartum women at risk for adverse cardiovascular outcomes and provide them with preventative therapies.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years
Plain Language Summary
Simplified for easier understanding
This study collects biological samples and health data from pregnant women during and after pregnancy to understand why some women develop preeclampsia (dangerously high blood pressure during pregnancy) and how it affects long-term heart health, using advanced multi-omics analysis (studying genes, proteins, and other biological data together).
**You may be eligible if...**
- You are 18 to 50 years old
- You are 10 to 24 weeks pregnant at enrollment
- You are carrying a single baby
- You plan to deliver at UC San Diego or Vanderbilt University Medical Center
**You may NOT be eligible if...**
- You are unable to give informed consent
- Your baby has a known chromosomal or structural abnormality, or the pregnancy has ended
- You have a history of cancer requiring major surgery or chemotherapy
- You are carrying multiples (twins, triplets, etc.)
- You have a known chromosomal abnormality (mother or baby)
- You plan to keep your placenta after delivery
- You are institutionalized for a psychiatric condition or incarcerated
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06340152
Related Trials
Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies
NCT054341952 locations
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
NCT067851161 location
Treatment With Aspirin After Preeclampsia: TAP Trial
NCT062816651 location
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
NCT064081811 location
Mechanisms of Pregnancy Vascular Adaptations
NCT038062831 location